Development and Validation of a Diabetic Retinopathy Risk Stratification Algorithm [0.03%]
糖尿病视网膜病变风险分层算法的开发与验证
Dariusz Tarasewicz,Andrew J Karter,Noel Pimentel et al.
Dariusz Tarasewicz et al.
Objective: Although diabetic retinopathy is a leading cause of blindness worldwide, diabetes-related blindness can be prevented through effective screening, detection, and treatment of disease. The study goal was to devel...
CRP, C-Peptide, and Risk of First-Time Cardiovascular Events and Mortality in Early Type 2 Diabetes: A Danish Cohort Study [0.03%]
C反应蛋白、胰岛素C肽值与2型糖尿病患者首次心血管事件和死亡风险的关联：一项丹麦队列研究
Anne Gedebjerg,Mette Bjerre,Alisa Devedzic Kjaergaard et al.
Anne Gedebjerg et al.
Objective: We investigated the relationship between hs-CRP, a marker of low-grade inflammation, alone or in combination with C-peptide, a marker of hyperinsulinemia/insulin resistance, and risk for cardiovascular events (...
Psychiatric Morbidity in Women With Previous Gestational Diabetes Mellitus: A Nationwide Register-Based Cohort Study [0.03%]
妊娠期糖尿病妇女的精神疾病发病率：一项基于全国登记记录的队列研究
Maria Hornstrup Christensen,Marianne Skovsager Andersen,Katrine Hass Rubin et al.
Maria Hornstrup Christensen et al.
Objective: To investigate associations between previous gestational diabetes mellitus (GDM) and incident psychiatric morbidity, and to explore the role of subsequent diabetes development in psychiatric morbidity risk. ...
Impact of Early Life Factors on Metabolic Phenotypes of Obesity in Preschool Children [0.03%]
学龄前儿童肥胖代谢特征的早期生命影响因素研究
Zijun Liao,Xianghui Xie,Jing Wang et al.
Zijun Liao et al.
Objective: To investigate the impact of factors in the first 1,000 days of life on metabolic phenotypes of obesity in preschool children in a cohort study. ...
Novel Once-Weekly Basal Insulin Fc Achieved Similar Glycemic Control With a Safety Profile Comparable to Insulin Degludec in Patients With Type 1 Diabetes [0.03%]
一种新型一周一次的基础胰岛素Fc与德谷胰岛素类似，在1型糖尿病患者中具有相似的血糖控制和相当的安全性
Christof M Kazda,Juliana M Bue-Valleskey,Jenny Chien et al.
Christof M Kazda et al.
Objective: Basal Insulin Fc (BIF; insulin efsitora alfa; LY3209590), a fusion protein combining a novel single-chain insulin variant with a human IgG Fc domain, is designed for once-weekly basal insulin administration. Th...
Randomized Controlled Trial
Diabetes care. 2023 May 1;46(5):1052-1059. DOI:10.2337/dc22-2395 2023
Potential and Pitfalls of ChatGPT and Natural-Language Artificial Intelligence Models for Diabetes Education [0.03%]
糖尿病教育中潜在的机遇与挑战：ChatGPT和自然语言人工智能模型的作用及其局限性
Gerald Gui Ren Sng,Joshua Yi Min Tung,Daniel Yan Zheng Lim et al.
Gerald Gui Ren Sng et al.
Personalized Virtual Care Using Continuous Glucose Monitoring in Adults With Type 2 Diabetes Treated With Less Intensive Therapies [0.03%]
使用持续葡萄糖监测进行成人2型糖尿病患者的个性化虚拟护理（接受较少强度治疗的患者）
Sushma Reddy,Calvin C Wu,Aimée José et al.
Sushma Reddy et al.
Abatacept for Delay of Type 1 Diabetes Progression in Stage 1 Relatives at Risk: A Randomized, Double-Masked, Controlled Trial [0.03%]
巴利昔单抗对1期糖尿病高危亲属的作用：一项随机双盲对照实验
William E Russell,Brian N Bundy,Mark S Anderson et al.
William E Russell et al.
Objective: Previous studies showed that inhibiting lymphocyte costimulation reduces declining β-cell function in individuals newly diagnosed with type 1 diabetes. We tested whether abatacept would delay or prevent progre...
Clinical Trial
Diabetes care. 2023 May 1;46(5):1005-1013. DOI:10.2337/dc22-2200 2023
Biomarker Changes Associated With Both Dulaglutide and Cardiovascular Events in the REWIND Randomized Controlled Trial: A Nested Case-Control Post Hoc Analysis [0.03%]
REWIND随机对照试验中与杜拉鲁肽和心血管事件相关的生物标志物变化：病例对照非预先指定的探索性事后分析
Hertzel C Gerstein,Shun-Fu Lee,Guillaume Paré et al.
Hertzel C Gerstein et al.
Objective: The glucagon-like peptide-1 receptor agonist dulaglutide reduced MACE in the Researching Cardiovascular Events with a Weekly Incretin in Diabetes (REWIND) trial. This article expores the relationship of selecte...
Randomized Controlled Trial
Diabetes care. 2023 May 1;46(5):1046-1051. DOI:10.2337/dc22-2397 2023
Evaluation of the Clinical Impact of Dapagliflozin Discontinuation as Adjunctive Therapy for Patients With Type 1 Diabetes After Indication Withdrawal: A Two-Center Retrospective Study [0.03%]
德pagliflozin作为辅助治疗在1型糖尿病患者中的临床影响评估：一项撤市后的两中心回顾性研究
José Ignacio Martínez-Montoro,María José Picón-César,Víctor José Simón-Frapolli et al.
José Ignacio Martínez-Montoro et al.